Background: The epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and erlotinib work for advanced non-small cell lung cancer (NSCLC). 50% or a worth for the check? ?.1 was thought to be indicating significant heterogeneity and a random-effects model was used; in any other case, a fixed-effects model was utilized. A subgroup evaluation of PFS,… Continue reading Background: The epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and